Aidoc Review

Aidoc is clinical AI for hospitals, and the problem it addresses is unglamorous but genuinely serious: a radiologist's worklist is usually ordered by when scans arrived, not by which patient is in the most danger.

Its software reads imaging as it comes in, identifies suspected urgent findings, and moves those cases forward in the queue. A suspected intracranial haemorrhage stops waiting behind a routine follow-up.

This review covers the platform, the clinical areas it covers, the outcome figures Aidoc publishes, and the questions a health system should ask before signing — because this is a procurement decision with patient-safety consequences, not a software trial.

Aidoc For Busy Readers

• What it is: clinical AI that analyses medical imaging and pushes urgent findings to the top of the queue, sold to hospitals and health systems.
• The platform: aiOS as the enterprise layer and CARE as the underlying foundation model, rather than a collection of single-purpose algorithms.
• Where it works: radiology, cardiology, neurovascular including stroke and intracranial haemorrhage, vascular disease, and incidental findings.
• Scale: Aidoc states deployment across 1,600+ medical centres, and cites the largest portfolio of FDA-cleared radiology algorithms.
• Not for individuals. There is no consumer or clinician-level version — this is a health system procurement.

Is Aidoc Right For Your Organisation?

Worth Evaluating If

• You run imaging volume high enough that queue order affects outcomes
• Stroke, PE, or haemorrhage pathways are a clinical priority
• Incidental findings are being lost between departments
• You want one platform rather than several separately integrated algorithms
• You have clinical governance capacity to oversee an AI deployment

Not Appropriate If

• You are an individual clinician looking for a personal tool
• You expect it to reduce radiologist workload rather than reorder it
• There is no capacity for integration and change management
• Nobody will own accountability for acting on AI-generated alerts
• You need a documentation or administrative tool, not imaging triage

Aidoc Clinical And Deployment Detail

Triage Is The Whole Idea

Most discussion of medical AI focuses on diagnostic accuracy — can it match a radiologist. Aidoc's proposition is different and, in practice, more achievable: change the order in which humans look at things.

The radiologist still reads the scan and still makes the call. What changes is that the scan showing a probable pulmonary embolism reaches them sooner, because the software flagged it while it was sitting in a queue.

This framing matters for how the tool should be judged. A false positive costs a radiologist a few seconds of attention. A missed urgent finding costs considerably more, which is why triage tools are tuned toward sensitivity.

The clinical value is not in the software being right. It is in the right scan being looked at first.

aiOS And CARE

Aidoc's architecture is worth understanding, because it is what distinguishes the company from vendors selling one algorithm for one condition.

The Platform Layer

aiOS is the enterprise platform that everything runs on. For a hospital, that matters more than any individual algorithm — integrating one AI tool into imaging workflow is a project, and integrating eight separately is an ordeal.

A single platform means one integration, one set of controls, and one place where clinical AI is governed.

The Foundation Model

CARE is Aidoc's foundation model, the layer beneath the individual clinical applications. The strategic bet is that a general model of medical imaging generalises better than a collection of narrow, separately trained detectors.

Whether that bet pays off is genuinely an open question in medical AI, and one worth asking the vendor about directly rather than accepting at face value.

Beyond The Read

Care coordination and patient management extend past the scan itself. Incidental findings capture is the clearest example — something noticed on a scan taken for another reason, which historically gets lost between departments.

That is a workflow failure rather than a diagnostic one, and it is a good fit for software.

The Clinical Range

Coverage is broader than most clinical AI vendors, spanning several specialties rather than concentrating on one.

• Radiology — imaging analysis and worklist prioritisation across modalities
• Neurovascular — stroke, brain aneurysm, spine, and intracranial haemorrhage
• Vascular — venous thromboembolism, aortic disease, and IVC filters
• Cardiology — coronary artery disease and echocardiography
• Incidental findings — capture and follow-up of findings outside the original clinical question

The Outcome Figures, And How To Read Them

Aidoc publishes specific operational figures: 31% faster time-to-notification for pulmonary embolism patients, a 34% reduction in door-to-puncture time for stroke patients, and 99% of eligible aortic aneurysm patients scheduled for follow-up.

These are the right kind of metrics — time-to-treatment in stroke and PE is directly linked to outcomes, so speeding it up is meaningful rather than cosmetic.

They are also vendor-reported, drawn from selected deployments, and we report them as such. A hospital evaluating Aidoc should ask which sites produced these numbers, what the baseline was, and whether the comparison was contemporaneous — the standard questions for any before-and-after clinical claim.

What A Health System Should Ask First

Buying clinical AI is unlike buying other software, and the evaluation should reflect that.

1. Establish which specific algorithms are FDA-cleared for your intended use, rather than accepting a portfolio-level claim.
2. Ask what the false positive rate looks like in a population like yours, not in the validation set.
3. Work out where alerts land in the actual clinical workflow, and who is accountable for acting on them.
4. Agree what happens when the software is wrong — in both directions — before go-live, not after an incident.
5. Check integration with your existing PACS and reporting systems, since this is where deployments usually stall.
6. Plan for alert fatigue explicitly: measure how often clinicians dismiss flags after three months, not after three weeks.

Adoption As Evidence

Aidoc states deployment across more than 1,600 medical centres, naming health systems including Mount Sinai, Yale New Haven Health, Houston Methodist, Ochsner, Sutter, Mercy, and UT Southwestern.

In healthcare, adoption at that scale carries real evidential weight. Academic medical centres do not put software into diagnostic pathways without clinical governance review, so each named deployment represents a passed institutional assessment.

It is still a vendor-stated list. But it is the kind of claim that is checkable and would be conspicuous if wrong.

Honest Limitations

Alert fatigue is the most serious practical risk. Triage tools are tuned for sensitivity, which means false positives, and clinicians who learn to dismiss flags reflexively have lost the benefit while keeping the interruption.

It does not reduce radiologist workload. Aidoc changes the order of reading, not the amount, so anyone hoping for staffing relief is measuring the wrong thing.

Performance varies by population. Models trained on one demographic mix can behave differently on another, and this is under-examined across the whole field, not just at Aidoc.

And it is an enterprise commitment. Integration, clinical governance, training, and change management are the real cost, and the software licence is often the smaller half of it.